Ligelizumab
From Wikipedia, the free encyclopedia
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | IGHE |
Clinical data | |
Legal status | ? |
Identifiers | |
CAS number | 1322627-61-1 |
ATC code | None |
Chemical data | |
Formula | ? |
Ligelizumab (INN) is a humanized monoclonal antibody that binds to IGHE. It acts as an immunomodulator.[1]
References
- ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information 26 (2).
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.